间充质干细胞来源外泌体促心肌梗死血管新生及其机制研究进展

血管新生(angiogenesis)是机体内一个复杂的生理学和病理学过程,是治疗缺血性疾病的重要措施。大量实验研究已表明间充质干细胞(mesenchymal stem cells, MSCs)等干细胞移植可促进心肌梗死后血管新生,近期研究证实这一作用可能主要通过分泌外泌体形式介导。外泌体(exosome)通过传递与血管新生相关微RNA(microRNA, mi RNA)或蛋白质等生物活性物质,调控靶器官中与血管新生相关通路的基因表达,提高内皮细胞在缺血缺氧环境下的存活、迁移、成管能力,促进心肌梗死区域血管新生。通过基因修饰手段增强外泌体介导的心脏修复作用,以及将外泌体与生物活性肽结合形成工程外泌体来靶向缺血心肌治疗,是目前外泌体在心血管领域的热点研究方向。本文结合近年外泌体研究的相关文献,就MSCs来源外泌体促进心肌梗死血管新生的具体机制及现状研究作一综述。     

脂肪间充质干细胞来源外泌体的功能

外泌体是细胞外膜质纳米囊泡,将蛋白质、核酸(DNA和RNA)转运到靶细胞中,介导局部和系统的细胞间通信,从而改变受体细胞的行为.这些小泡在许多生物功能中发挥重要作用,如脂肪合成、免疫调节、神经再生和肿瘤调节等.脂肪间充质干细胞目前被认为是细胞治疗和再生医学领域中一种功能丰富的工具,可产生和分泌多种外泌体,继承细胞的多种...     

间充质干细胞外泌体治疗肺部疾病的研究进展

肺部疾病作为一种呼吸系统常见病,与重工业快速发展、环境污染等密切相关,死亡率极高。近来研究发现间充质干细胞(mesenchymal stem cells,MSCs)能够自主归巢至疾病损伤部位、修复受损组织并参与调节全身炎症和免疫反应,在临床上有较好的应用前景。外泌体是一种细胞外膜囊泡,可能通过调节细胞间通讯参与生物系统中的各种活动,分泌至细胞外环境的外泌体也会影响宿主免疫系统。而MSCs外泌体作为MSCs旁分泌过程中的一种介质,携带有蛋白质、脂质、m RNA和microRNA等生物活性物质,比基于细胞的治疗有更高的安全性,其潜在的医学价值受到了研究者的广泛关注。本文综述了近年来研究中MSCs外泌体在常见肺部疾病治疗中的作用机制,将为其在未来的临床应用方面提供依据。     

人嗅觉黏膜间充质干细胞来源的外泌体促进内皮细胞的血管生成

外泌体作为是细胞旁分泌的重要介质,在促血管形成方面有重要作用。在我们前期研究中,已经成功从嗅黏膜间充质干细胞（olfactory mucosa mesenchymal stem cells,OM-MSCs）分离、鉴定了其外泌体,然而,OM-MSCs源外泌体对血管生成的影响尚不清楚。本研究旨在探讨OM-MSCs来源外泌体对内皮细胞血管生成能力的影响。采用PKH67 荧光标记OM-MSCs源外泌体,与人脑微血管内皮细胞（human brain microvessel endothelial cells, HBMECs) 共培养,观察 OM-MSCs外泌体能否进入 HBMECs。采用CCK-8法、Transwell 迁移实验和小管实验,观察 OM-MSCs外泌体对 HBMECs增殖、迁移及管状结构形成的影响。采用基质胶塞实验及CD31免疫荧光,观察OM-MSCs外泌体在体内对血管生成的影响。上述研究均以等量 PBS 作为对照。结果提示,OM-MSCs外泌体可被HBMECs 摄取。CCK-8 法检测显示,在处理1、2、3、4、5 d各时间点,实验组细胞增殖均优于对照组（1.32±0.14 vs. 0.98±0.04, 1.36±0.14 vs.1.04±0.06, 1.75±0.18 vs.1.33±0.11, 2.16±0.11 vs.1.50±0.19, 2.71±0.11 vs. 1.81±0.20, P<0.01）。Transwell 实验结果显示,实验组跨膜迁移细胞吸光度值较对照组显著增多（1.12±0.05 vs.0.02±0.02, P<0.05）。在体外小管实验中,从节点、交叉点、网眼数、血管分支数和总长度5个方面,实验组均高于空白对照组（374.33±127.74 vs. 193.33±44.79, 104.56±33.07 vs. 54.33±11.65, 20.11±11.20 vs. 7.56±3.64, 81.67±19.07 vs. 57.00±13.02, 11466.22±2781.03 vs. 8544.00±1848.61, P<0.05）;在体内实验中,实验组成血管及CD31阳性率（%）亦显著高于对照组（85.00±5.57 vs.8.00±2.08, P<0.05）。本研究表明：OM-MSCs外泌体可促进 HBMECs 增殖、迁移及管样结构形成,提示OM-MSCs外泌体可促进血管新生。     

人嗅觉黏膜间充质干细胞来源的外泌体促进内皮细胞的血管生成

外泌体作为是细胞旁分泌的重要介质,在促血管形成方面有重要作用。在我们前期研究中,已经成功从嗅黏膜间充质干细胞（olfactory mucosa mesenchymal stem cells,OM-MSCs）分离、鉴定了其外泌体,然而,OM-MSCs源外泌体对血管生成的影响尚不清楚。本研究旨在探讨OM-MSCs来源外泌体对内皮细胞血管生成能力的影响。采用PKH67 荧光标记OM-MSCs源外泌体,与人脑微血管内皮细胞（human brain microvessel endothelial cells, HBMECs) 共培养,观察 OM-MSCs外泌体能否进入 HBMECs。采用CCK-8法、Transwell 迁移实验和小管实验,观察 OM-MSCs外泌体对 HBMECs增殖、迁移及管状结构形成的影响。采用基质胶塞实验及CD31免疫荧光,观察OM-MSCs外泌体在体内对血管生成的影响。上述研究均以等量 PBS 作为对照。结果提示,OM-MSCs外泌体可被HBMECs 摄取。CCK-8 法检测显示,在处理1、2、3、4、5 d各时间点,实验组细胞增殖均优于对照组（1.32±0.14 vs. 0.98±0.04, 1.36±0.14 vs.1.04±0.06, 1.75±0.18 vs.1.33±0.11, 2.16±0.11 vs.1.50±0.19, 2.71±0.11 vs. 1.81±0.20, P<0.01）。Transwell 实验结果显示,实验组跨膜迁移细胞吸光度值较对照组显著增多（1.12±0.05 vs.0.02±0.02, P<0.05）。在体外小管实验中,从节点、交叉点、网眼数、血管分支数和总长度5个方面,实验组均高于空白对照组（374.33±127.74 vs. 193.33±44.79, 104.56±33.07 vs. 54.33±11.65, 20.11±11.20 vs. 7.56±3.64, 81.67±19.07 vs. 57.00±13.02, 11466.22±2781.03 vs. 8544.00±1848.61, P<0.05）;在体内实验中,实验组成血管及CD31阳性率（%）亦显著高于对照组（85.00±5.57 vs.8.00±2.08, P<0.05）。本研究表明：OM-MSCs外泌体可促进 HBMECs 增殖、迁移及管样结构形成,提示OM-MSCs外泌体可促进血管新生。     

间充质干细胞来源外泌体在骨关节炎治疗中的作用

骨关节炎(OA)是最常见的慢性退行性骨关节疾病,目前对骨关节炎的治疗还没有特效疗法。间充质干细胞(MSC)对软骨修复有较好的疗效,间充质干细胞来源外泌体可能在这一治疗过程中发挥重要作用。外泌体是细胞间的通讯载体,能在细胞间传递生物活性脂质、核酸以及蛋白质等生物活性分子对骨关节炎产生一定影响。本文就探讨间充质干细胞来源的外泌体治疗骨关节炎过程中的作用机制与可行性做出综述。     

间充质干细胞外泌体在阿尔兹海默症治疗中的研究进展

阿尔兹海默症（AD）是一种病理机制复杂,以进行性认知功能障碍为主的中枢神经系统疾病,目前仍缺乏有效的治疗方法。多项研究结果显示,间充质干细胞（MSCs）外泌体能够促进抗炎、调节免疫功能、加强Aβ降解、促进神经细胞轴突生长等,能很好地针对AD的核心病理机制发挥效果从而达到治疗效果。本文主要介绍MSCs外泌体在各项AD病理机制治疗中的研究进展。     

Multifunctional role of microRNAs in mesenchymal stem cell-derived exosomes in treatment of diseases

Mesenchymal stem cells can be replaced by exosomes for the treatment of inflammatory diseases, injury repair, degenerative diseases, and tumors. Exosomes are small vesicles rich in a variety of nucleic acids [including messenger RNA, Long non-coding RNA, microRNA (miRNA), and circular RNA], proteins, and lipids. Exosomes can be secreted by most cells in the human body and are known to play a key role in the communication of information and material transport between cells. Like exosomes, miRNAs were neglected before their role in various activities of organisms was discovered. Several studies have confirmed that miRNAs play a vital role within exosomes. This review focuses on the specific role of miRNAs in MSC-derived exosomes (MSC-exosomes) and the methods commonly used by researchers to study miRNAs in exosomes. Taken together, miRNAs from MSC-exosomes display immense potential and practical value, both in basic medicine and future clinical applications, in treating several diseases.     

Pluripotent stem cell-derived mesenchymal stromal cells improve cardiac function and vascularity after myocardial infarction

Background aimsMesenchymal stromal cells (MSCs) have been shown to improve cardiac function after injury and are the subject of ongoing clinical trials. In this study, the authors tested the cardiac regenerative potential of an induced pluripotent stem cell-derived MSC (iPSC-MSC) population (Cymerus MSCs) in a rat model of myocardial ischemia-reperfusion (I/R). Furthermore, the authors compared this efficacy with bone marrow-derived MSCs (BM-MSCs), which are the predominant cell type in clinical trials.MethodsFour days after myocardial I/R injury, rats were randomly assigned to (i) a Cymerus MSC group (n = 15), (ii) a BM-MSC group (n = 15) or (iii) a vehicle control group (n = 14). For cell-treated animals, a total of 5 × 10⁶ cells were injected at three sites within the infarcted left ventricular (LV) wall.ResultsOne month after cell transplantation, Cymerus MSCs improved LV function (assessed by echocardiography) compared with vehicle and BM-MSCs. Interestingly, Cymerus MSCs enhanced angiogenesis without sustained engraftment or significant impact on infarct scar size. Suggesting safety, Cymerus MSCs had no effect on inducible tachycardia or the ventricular scar heterogeneity that provides a substrate for cardiac re-entrant circuits.ConclusionsThe authors here demonstrate that intra-myocardial administration of iPSC-MSCs (Cymerus MSCs) provide better therapeutic effects compared with conventional BM-MSCs in a rodent model of myocardial I/R. Because of its manufacturing scalability, iPSC-MSC therapy offers an exciting opportunity for an “off-the-shelf” stem cell therapy for cardiac repair.     

间充质干细胞外泌体对海马星形胶质细胞活化的抑制作用研究

目的 探讨间充质干细胞外泌体(MSC-Exo)对海马星形胶质细胞活化的抑制作用.方法 实验通过超速离心法提取脐带MSC-Exo,并使用PKH-26染料标记;MSC-Exo预处理原代海马星形胶质细胞后使用脂多糖(LPS)诱导细胞活化,并分为对照组、LPS组和LPS+MSC-Exo组,进而行免疫细胞化学检测胶质纤维酸性蛋白...     

干细胞来源外泌体在骨关节炎的病理生理发展进程的作用和诊断治疗的研究进展

在过去的十几年中,随着外泌体(从细胞释放的囊泡)的发现,鉴定和研究的深入,除了诸多研究发现病理情况下细胞分泌的外泌体对于骨关节炎疾病的病理生理进程具有重要作用之外,还发现了外泌体作为良好的生物信号传递因子,具有更加强大的软骨再生修复的应用潜能。合理调控和抑制"致病的"外泌体,合理利用"优良的"外泌体,对于骨关节炎的病理进程的控制和疾病的治疗都具有重要的意义。本文主要综述在骨关节炎疾病中外泌体的主要致病作用和机制,以及使用干细胞来源外泌体进行骨关节炎疾病治疗的研究进展。     

Effect of mesenchymal stem cell-derived exosomes on the induction of mouse tolerogenic dendritic cells

Dendritic cells (DCs) orchestrate innate inflammatory responses and adaptive immunity through T-cell activation via direct cell–cell interactions and/or cytokine production. Tolerogenic DCs (tolDCs) help maintain immunological tolerance through the induction of T-cell unresponsiveness or apoptosis, and generation of regulatory T cells. Mesenchymal stromal cells (MSCs) are adult multipotent cells located within the stroma of bone marrow (BM), but they can be isolated from virtually all organs. Extracellular vesicles and exosomes are released from inflammatory cells and act as messengers enabling communication between cells. To investigate the effects of MSC-derived exosomes on the induction of mouse tolDCs, murine adipose-derived MSCs were isolated from C57BL/6 mice and exosomes isolated by ExoQuick-TC kits. BM-derived DCs (BMDCs) were prepared and cocultured with MSCs-derived exosomes (100 μg/ml) for 72 hr. Mature BMDCs were derived by adding lipopolysaccharide (LPS; 0.1μg/ml) at Day 8 for 24 hr. The study groups were divided into (a) immature DC (iDC, Ctrl), (b) iDC + exosome (Exo), (c) iDC + LPS (LPS), and (d) iDC + exosome + LPS (EXO + LPS). Expression of CD11c, CD83, CD86, CD40, and MHCII on DCs was analyzed at Day 9. DC proliferation was assessed by coculture with carboxyfluorescein succinimidyl ester-labeled BALB/C-derived splenocytes p. Interleukin-6 (IL-6), IL-10, and transforming growth factor-β (TGF-β) release were measured by enzyme-linked immunosorbent assay. MSC-derived exosomes decrease DC surface marker expression in cells treated with LPS, compared with control cells ( ≤ .05). MSC-derived exosomes decrease IL-6 release but augment IL-10 and TGF-β release (p ≤ .05). Lymphocyte proliferation was decreased (p ≤ .05) in the presence of DCs treated with MSC-derived exosomes. CMSC-derived exosomes suppress the maturation of BMDCs, suggesting that they may be important modulators of DC-induced immune responses.     

间充质干细胞源性外泌体miRNAs参与损伤心血管细胞修复的研究进展

外泌体是由各种组织和细胞所释放的细胞外囊泡,在细胞之间充当各种分子(包括蛋白质,脂质和RNA)的载体,从而调节或干预特定的生理过程.MiRNAs是一类小的非编码RNA,能够靶向多个mRNA并诱导其降解或翻译抑制以调控相关基因表达.目前对外泌体内微小RNA(miR-NAs)的研究最为广泛.间充质干细胞(MSCs)是一种多...     

Immunomodulation: The next target of mesenchymal stem cell-derived exosomes in the context of ischemic stroke

Ischemic stroke(IS) is the most prevalent form of brain disease, characterized by high morbidity, disability, and mortality. However, there is still a lack of ideal prevention and treatment measures in clinical practice. Notably, the transplantation therapy of mesenchymal stem cells(MSCs) has been a hot research topic in stroke. Nevertheless, there are risks associated with this cell therapy, including tumor formation, coagulation dysfunction, and vascular occlusion. Also, a growing number of st...